Orchestra BioMed Holdings, Inc. OBIO

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
45/100
Developing

Ranked against 712 peers in Biotechnology

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of … Full OBIO analysis →

Key strengths

  • Operating Expense Control OpEx growth is controlled (score 0.68), demonstrating operating leverage.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.64), providing operational cushion.

Key risks

  • ROIC Below WACC or Peers ROIC at 38.5th percentile suggests inefficient capital deployment.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.18), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
35
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where OBIO ranks in Biotechnology

Orchestra BioMed Holdings, Inc. ranks #306 of 713 scored companies in Biotechnology by moat score — the top 43%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
302 Alpha Cognition Inc. ACOG 45/100 Developing
303 Alterity Therapeutics Limited ATHE 45/100 Developing
304 EyePoint Pharmaceuticals, Inc. EYPT 45/100 Developing
305 Aptevo Therapeutics Inc. APVO 45/100 Developing
306 Orchestra BioMed Holdings, Inc. OBIO 45/100 Developing
307 IN8bio, Inc. INAB 45/100 Developing
308 Kezar Life Sciences, Inc. KZR 45/100 Developing
309 Bicara Therapeutics Inc. BCAX 44/100 Developing
310 Nutriband Inc. Warrant NTRBW 44/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How OBIO scores on the Corporate Default defenses

Pricing Power

Score 35 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 69 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 47 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 21 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 56 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 47 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding OBIO's moat

What is Orchestra BioMed Holdings, Inc.'s moat score?

Orchestra BioMed Holdings, Inc. (OBIO) scores 45 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #306 of 713 scored companies in Biotechnology, the top 43%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (69/100) and its weakest is Capital Efficiency (21/100).

How does Orchestra BioMed Holdings, Inc. compare with other Biotechnology companies?

Orchestra BioMed Holdings, Inc. ranks #306 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Aptevo Therapeutics Inc. (APVO) at 45 just above it and IN8bio, Inc. (INAB) at 44 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Orchestra BioMed Holdings, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Orchestra BioMed Holdings, Inc.?

The Corporate Default template measures 6 defenses, and OBIO scores: Pricing Power (35), Cost Advantage (69), Customer Stickiness (47), Capital Efficiency (21), Resilience (56), Scale & Market Position (47). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000